These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 32443941)

  • 1. Direct Oral Anticoagulants in Obesity: An Updated Literature Review.
    Sebaaly J; Kelley D
    Ann Pharmacother; 2020 Nov; 54(11):1144-1158. PubMed ID: 32443941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dilemmas Related to Direct-Acting Oral Anticoagulant Administration in Patients With Extreme Obesity.
    Erstad BL; Barletta JF
    Ann Pharmacother; 2023 Jun; 57(6):727-737. PubMed ID: 36258660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review.
    Zhao Y; Guo M; Li D; Xu W; Pan C; He C; Cui X
    Clin Appl Thromb Hemost; 2023; 29():10760296231153638. PubMed ID: 36760080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
    Kido K; Ngorsuraches S
    Ann Pharmacother; 2019 Feb; 53(2):165-170. PubMed ID: 30130979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.
    Kalani C; Awudi E; Alexander T; Udeani G; Surani S
    Hosp Pract (1995); 2019 Oct; 47(4):181-185. PubMed ID: 31580732
    [No Abstract]   [Full Text] [Related]  

  • 7. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 8. A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants.
    Cohen AT; Hill NR; Luo X; Masseria C; Abariga SA; Ashaye AO
    Int J Cardiol; 2018 Oct; 269():174-181. PubMed ID: 30037626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
    Russo V; Cattaneo D; Giannetti L; Bottino R; Laezza N; Atripaldi U; Clementi E
    Clin Ther; 2021 Sep; 43(9):e255-e263. PubMed ID: 34366151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease.
    Starr JA; Pinner NA; Mannis M; Stuart MK
    Ann Pharmacother; 2022 Jun; 56(6):691-703. PubMed ID: 34459281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations.
    Stacy ZA; Richter SK
    Ther Adv Cardiovasc Dis; 2018 Sep; 12(9):247-262. PubMed ID: 30081727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosing of Target-Specific Oral Anticoagulants in Special Populations.
    Morrill AM; Ge D; Willett KC
    Ann Pharmacother; 2015 Sep; 49(9):1031-45. PubMed ID: 26104052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edoxaban: A direct oral anticoagulant.
    Poulakos M; Walker JN; Baig U; David T
    Am J Health Syst Pharm; 2017 Feb; 74(3):117-129. PubMed ID: 28122753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations.
    Covert K; Branam DL
    Am J Health Syst Pharm; 2020 May; 77(11):865-876. PubMed ID: 32426845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Direct Oral Anticoagulants in Morbidly Obese Patients.
    Kido K; Lee JC; Hellwig T; Gulseth MP
    Pharmacotherapy; 2020 Jan; 40(1):72-83. PubMed ID: 31834939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
    Darius H
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation and BMI: effect of high body weight on the safety and efficacy of direct oral anticoagulants.
    Mausteller KG; Eisele CD; Julian K; Patel P; Bansal A; Jain R; Jain R
    Future Cardiol; 2022 Sep; 18(10):829-837. PubMed ID: 36052844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience.
    Eikelboom J; Merli G
    Am J Med; 2016 Nov; 129(11S):S33-S40. PubMed ID: 27586367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.